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w/o, 28% with TLR5-stop) and a signiﬁcant increase of 1yr TRM
(25% to 39%, p 0.01) as well as overall TRM, which translated
in decreased overall survival (51% vs 33%, p 0.002). The effect
was strongest in the subgroup of younger and early stage pts
receiving HLA-identical sibling SCT; in addition, combined
analysis of TLR5-stop and NOD2/CARD15 SNPs suggested a
potential synergism, as 1 yr TRM was 21% in the absence of
both SNPs, 32 and 33% in the presence of either TLR5-stop or
NOD2/CARD15 and 66% in the presence of both. In multivar-
iate cox regression analysis of risk factors for 1yr TRM, older
recipient age (HR1.5, p 0.04), female donor in a male recipient
(HR 1.7, p 0.01) and presence of TLR5-stop (HR 1.6, p 0.05) and
NOD2/CARD15 SNPs (HR 1.8, p 0.004) in the recipient were
conﬁrmed as independent risk factors.
As both, TLR- stop and NOD2/CARD15 SNPs have been associ-
ated with functional defects, our observations further support the
concept of a major role of altered innate immune responses in the
pathophysiology of GvHD associated complications following al-
logeneic SCT.
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IMMATURE DENDRITIC CELLS DOWNREGULATE GRAFT VERSUS HOST
REACTIONS IN THE HUMAN SKIN EXPLANT MODEL AFTER CO-CUL-
TURE WITH IN VITRO PUVA TREATED LYMPHOCYTES
Holtick, U.1, Marshall, S.P.1, Hilkens, C.M.U.2, Wang, X.N.1,
Dickinson, A.M.1 1Haematological Sciences; 2Immunotherapy Group,
Medical School, Newcastle University, Newcastle upon Tyne, United
Kingdom.
Extracorporeal Photopheresis (ECP) can be successfully used
to treat steroid refractory Graft versus Host Disease (GvHD)
after allogeneic hematopoietic stem cell transplantation. ECP is
well tolerated and, different from conventional immunosuppres-
sants, does not increase infection or relapse rates. One suggested
scenario is that dendritic cells (iDC) might be modulated by
ECP treated apoptotic lymphocytes and aquire a tolerogenic
phenotype to downregulate inﬂammation in GvHD. We at-
tempted to test this hypothesis using the human skin explant
model.
Responder PBMCs and monocytes were derived from healthy
donor buffy coats. Skin and stimulator cells were derived from
patients after informed consent and ethical approval. A mixed
lymphocyte reaction was set up. On day 4 responder cells were
taken from the MLR. Apoptotic and dead cells were removed
before treating half of the cells with in vitro PUVA (Psoralen,
UVA) simulating ECP treatment. After 20h, the untreated or in
vitro PUVA treated cells were added to monocyte derived im-
mature DCs of responder origin and co-cultured overnight. The
respective dendritic cells then were isolated via FACS sorting
and added back to the ongoing MLR at a ratio of 1:10 (DC :
MLR responder). Immature DCs were added at the same ratio
to a third ﬂask. Medium and Responder cells served as negative
and positive control. After 48h 1106 responder cells from the
respective setup were given to skin sections derived from a
dermabrasio. After 3 days the skin was routinally ﬁxed and
stained before evaluating the GvH grade using the Lerner scale.
Results: Immature DCs which had been in co-culture with in
vitro PUVA treated PBMCs, but none of the controls, down-
regulated GvH reactions in the skin explant model from Grade
III to grade I. MLR supernatants tested so far show reduced
IFN- and TNF-
 levels but no difference in IL-10 and IL-4
production. We are currently extending cytokine analysis and
are further characterizing the apoptotic cells’ inﬂuence on DCs
in our model. FACS analysis of immature DCs after co-culture
with apoptotic cells revealed upregulation of PDL-1 as a pos-
sible mechanism for lymphocyte suppression. Further investi-
gation should reveal whether origin of the apoptotic cells or the
method apoptosis is induced by are relevant for the observed
effects.
Using the human skin explant model we could show that mod-
ulation of immature DCs by ECP/in vitro PUVA treated lympho-
cytes downregulates GvH reactions.
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SELECTIVE EXPANSION OF HUMAN REGULATORY (CD4CD25
CD127LOWFOXP3) CELLS TO HIGH PURITY BY INHIBITING EXPAN-
SION OF CD4CD25CD127HIGHFOXP3- CONVENTIONAL T CELLS
WITH RAPAMYCIN
Hou, J.-Z.1,2, Zambricki, E.1, Zeiser, R.1, Negrin, R.S.1 1Division of
Bone Marrow Transplantation, School of Medicine, Stanford University,
Stanford, CA; 2Division of Hematology, School of Medicine, Stanford
University, Stanford, CA.
CD4CD25FOXP3 natural occurring T regulatory (Treg) cells
possess great therapeutic potential as adoptive cellular therapy for
controlling acute GVHD. However, their clinical application is lim-
ited by the difﬁculty of obtaining sufﬁcient numbers of
CD4CD25FOXP3 cells. This study explored a strategy to ex-
pand human Treg in high purity and high numbers. By comparing
expression of cell surface molecules on sorted CD4CD25high vs.
CD4CD25- cells using mAb microarray, we identiﬁed CD127 was
highly expressed in CD4CD25- and CD4CD25Low cells in human
PBMC. Incorporating this new discovery, CD4CD25 cells were
isolated by CD25 selection from PBMC, sorted into
CD4CD25HighCD127Low and CD4CD25lowCD127High cells.
FOXP3 were positive in 94% of CD4CD25HighCD127Low cells,
and 5% in CD4CD25lowCD127High cells. The sorted cells were
expanded with and without rapamycin in X-vivo medium containing
IL-2 and anti-CD3/CD28 beads for a total of 21 days. In the absence
of rapamycin, CD4CD25HighCD127Low cells expanded expanded
156 and 1560 folds, yet only 30% and 20% of expanded cells were
positive for FOXP3 at day 14 and 21 respectively. In the presence of
rapamycin CD4CD25HighCD127Low cells remain FOXP3 in
96%, 60% and 56% at days 7, 14 and 21. However, the number of
cells increased only 19, 36, and 21 folds at days 7, 14 and 21 respec-
tively. To overcome the insufﬁcient expansion of
CD4CD25HighCD127Low cells in the presence of rapamycin, anti-
CD3mAb (OKT3) or anti-CD3/CD28 beads was added to the media
at day 7 after the initial beads were removed and cultured until day 21.
At day 14, 66% of the cells were FOXP3 positive with rapamycin and
anti-CD3 and 80% for cells with rapamycin and ani-CD3/CD28
beads. The numbers of cells were expanded: 13 folds with rapamycin
and anti-CD3, and 238 folds with rapamycin and ani-CD3/CD28
beads. At day 21, the numbers of cells were expanded: 34 folds with
rapamycin and anti-CD3, and 2856 folds with rapamycin and ani-
CD3/CD28 beads. In contrast, CD4CD25lowCD127High cells ex-
panded in the same condition as controls had much lower percentages
of FOXP3 cells. In summary, in the presence of rapamycin,
CD4CD25HighCD127LowFOXP3 cells were preferentially ex-
panded with IL-2 and anti-CD3/CD28 beads. Continued stimulation
from anti-CD3/CD28 beads enhanced the expansion of
CD4CD25HighCD127LowFOXP3 cells. The suppressive function
was positively correlated with the percentage of FOXP3 cells in the
MLR culture.
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TREATMENT OF SEVERE OCULAR SURFACE DISEASE FROM OCULAR
CHRONIC GRAFT-VERSUS-HOST DISEASE WITH A SCLERAL LEN PROS-
THETIC DEVICE
Jacobs, D.S.1,2, Rosenthal, P.1,2 1Boston Foundation for Sight, Needham,
MA; 2Harvard Medical School, Boston, MA.
Purpose: The ﬂuid-ventilated, gas-permeable scleral lens pros-
thetic device is an innovative treatment for ocular surface disease.
Retrospective studies of patients with severe dry eye ﬁtted with
these lenses report mitigation of symptoms, improvement in func-
tion and quality of life, and healing of persistent epithelial defects
of the corneal surface. This prospective study is designed to mea-
sure the impact of this device on visual function in patients with
ocular chronic graft-versus-host disease (cGvHD) unresponsive to
conventional therapy.
Methods: All patients referred to this institution for scleral lens
consultation from January through June 2006 were administered
the VFQ-25 at entry, and again 6 months later. The National Eye
Institute sponsored the development of the VFQ-25 as a standard-
ized, validated survey instrument to measure the dimensions of
self-reported vision-targeted health status in persons who have
Poster Session II 109
chronic eye diseases. Our patient database was sorted by diagnosis
to identify the cGvHD subgroup in this cohort. The characteristics
of this sub-group were extracted by database analysis and retro-
spective chart review. Initial VFQ-25 scores in this subgroup, their
scores at 6-month follow-up, and change in score for those ﬁtted
with the scleral lenses will be reported.
Results: There were 16 patients with ocular surface disease from
cGvHD seen for scleral lens consultation from January through
June 2006. Demographic breakdown reveals M:F  12:4, with age
distribution as follows: 21-30, n 2; 31-40, n  3; 41-50, n 3;
51-60, n6; 61-70, n2. Prior conventional therapy is reported.
Mean baseline composite score on the VFQ-25 was 62 (range
35-91, n16); scale is 0 – 100, with 100 representing highest level
of function. Of these 16 patients, 13 were ﬁtted with scleral lenses.
Mean score for patients not ﬁtted was 74 (n3), whereas mean
score for patients ﬁtted was 59 (n13). Preliminary analysis of data
on patients who have reached the 6-month follow-up (n6) reveals
that each patient ﬁtted had improvement of function. Mean score
at 6 months is 70.5 (n6). Mean change in score for the 6 patients
for whom there is 6-month follow-up is 20.6 (n6), with range
from 2 to  45.
Conclusion: The ﬂuid-ventilated gas permeable scleral lens
prosthetic device improves visual function in patients with ocular
cGvHD unresponsive to conventional therapy.
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INCIDENCE AND OUTCOME OF CHRONIC GRAFT-VERSUS-HOST DIS-
EASE (CGVHD) AFTER ALLOGENEIC STEM CELL TRANSPLANT (SCT)
USING NATIONAL INSTITUTE OF HEALTH (NIH) CONSENSUS CRITERIA
Jagasia, M.1, Chinratanalab, W.2, Giglia, J.1, Dixon, S.1, Chen, H.1,
Frangoul, H.1, Engelhardt, B.1, Goodman, S.2, Greer, J.1, Kassim, A.1,
Morgan, D.1, Ruffner, K.1, Schuening, F.1 1Vanderbilt University
Medical Center, Nashville, TN; 2Veterans Administration Hospital,
Nashville, TN.
cGVHD, deﬁned as GVHD after day 100, is common, with an
impact on morbidity and survival. The limited/extensive cGVHD
classiﬁcation is not reproducible or prognostic for late non-relapse
mortality (NRM). Recently the NIH consensus criteria were pro-
posed, but the ability of these criteria to predict outcome of various
types of cGVHD is unknown.
Pts undergoing their 1st SCT from 1/01 to 12/03 were studied.
110 pts alive beyond day 100 met criteria for the study. GVHD
after day 100 was classiﬁed using NIH criteria into: persistent acute
GVHD (aGVHD) (assigned at day 100), recurrent aGVHD, de-
layed aGVHD, classic cGVHD, overlap GVHD (all assigned at
time of onset). Severity scores were assigned to pts with classic and
overlap GVHD at onset and clinical worsening. Overall survival
(OS) both from time of transplant and time of GVHD onset were
measured.
37 (34%) had no GVHD and 73 (66%) pts had GVHD. OS was
44% vs. 66% (no GVHD vs.GVHD, P0.026). Of 73 pts with
GVHD, 14 (19%) had limited and 59 (80%) had extensive
cGVHD. Pts with limited GVHD were reclassiﬁed as persistent
aGVHD (7%), recurrent aGVHD (29%), and classic CGVHD
(64%). Pts with extensive cGVHD were reclassiﬁed as persistent
(3%), delayed (3%), recurrent (31%), classic chronic (37%), and
overlap GVHD (26%). 31 (42%) had no subsequent clinical wors-
ening and 42 (58%) had subsequent clinical worsening of GVHD.
65% of pts with classic cGVHD (22/31) had worsening compared
to other types (20/42, 47%) (P0.046). Severity scores increased in
12/31 pts (39%) at time of subsequent clinical worsening. OS of pts
with various types of GVHD were signiﬁcantly different
(P0.0001). This was more apparent when pts with any acute
features of GVHD were compared with classic cGVHD (3-yr OS
47% vs. 66%, P0.0015). This effect persisted when survival was
measured from onset of GVHD (P0.0336). Severity at onset or
clinical worsening in pts with classic or overlap GVHD did not
impact survival. The 3-yr NRM (with relapse as a competing risk)
for the cohort was 21% and was not affected by the presence or
absence of GVHD, or subtypes of GVHD. Signiﬁcant variables
using Cox model with time dependent covariates were any
aGVHD feature after day 100 (HHR 5.27, P0.0004), and exten-
sive cGVHD (HR 0.28, P0.0041).
The OS with different NIH subtypes after day 100 from SCT
varies and is superior for pts with classic cGVHD. Global severity
score, within the limits of our study had no prognostic value with
respect to survival.
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RITUXIMAB RESPONSIVE REFRACTORY ACUTE GRAFT VERSUS HOST
DISEASE
Kamble, R.1,2,3, Phalak, K.2, Carrum, G.1,2,3, Oholendt, M.1,3,
Heslop, H.1,2,3, Brenner, M.1,2,3 1Center for Cell and Gene Therapy,
Houston, TX; 2Baylor College of Medicine, Houston, TX; 3The Meth-
odist Hospital, Houston, TX.
The prognosis of steroid refractory acute graft-versus-host dis-
ease (SR-aGVHD) is poor with suboptimal responses to currently
available agents. The role of B- lymphocytes in the pathogenesis of
GVHD is unclear, but recent reports of successful responses to
Rituximab in patients with cGvHD support the hypothesis that a
coordinated B and T cell response is instrumental in cGVHD. The
contribution of B-cells to the pathogenesis of aGVHD, however, is
unknown. We now report 3 patients who received Rituximab with
complete response of severe acute GVHD. The ﬁrst patient (ta-
ble-1) was a 51 year old female who developed severe transplant-
associated thrombotic thrombocytopenic purpura (TA-TTP),
manifesting as seizure, encephalopathy, cerebral edema, renal fail-
ure, fever and thrombocytopenia, which failed to respond to
methyl prednisone and 26 sessions of plasmapharesis. Rituximab
for refractory TTP was initiated on day  58, while plasma
exchange was continued. Following 3 doses of weekly Rituximab,
there was resolution of TTP. At the time of initiation of Ritux-
imab, the patient also had active grade III aGVHD that was
refractory to steroids. GVHD improvement was noted from day
79 with complete resolution of aGVHD on day95. During the
course of Rituximab, steroids were progressively tapered. Beyond
100 days she had limited cGVHD involving skin that was well
controlled on oral prednisone at 10 mg/day. 100% donor chimer-
ism was present. Two additional patients with refractory aGVHD
(Table 1) were then treated. Complete resolution of aGVHD
occurred in 2 weeks, but did not begin until several days after
stopping previous inﬂiximab/daclizumab therapy. This observation
of complete aGVHD responses to Rituximab in 3 patients requires
conﬁrmation in larger trial but suggests that B cells contribute to
the pathogenesis of both acute and chronic GvHD.
Table-1: Patient and disease characteristics of 3 patients with steroid
refractory aGVHD
Patient
Age/Sex
Diagnosis
Stage
Allogeneic
transplant
Organ
involved
aGVHD
grade
Previous
GVHD
Therapy
Timing/doses
of Rituximab
aGVHD
response Outcome
51 F DLBCL Mel-Flu-Alem
MUD/PBSCT
Skin III,
Gut III,
Grade
III
Steroids
(6.4 gm)
day 58 3
doses
Complete
residual
limited
cGVHD
Died of sepsis on
day 160
39 F CML BC CY/TBI MRD/
PBSCT
Skin III,
Liver II,
Gut III,
Grade
III
Steroids
(3.6 gm)
Infliximab
x6
day 61 2
doses
Complete
resolution
Alive in mCr
39 M AML M-7 CY/TBI/Alem
MUD/PBSCT
Liver II,
Gut IV,
Grade
IV
Steroids
(7.2 gm)
Infliximab
x5
Daclizumab
x4
day 49 4
doses
Complete
resolution
Alive in CR
Abbreviation: GVHD graft versus host disease, aGVHD acute
graft versus host disease, cGVHD chronic graft versus host
disease, F female, M male, DLBCL diffuse large B cell
lymphoma, Mel melphalan, Flu Fludarabine, Alem ale-
mtuzumab, MUD matched unrelated donor, PBSCT pe-
ripheral blood stem cell transplant, CML chronic myeloid
leukemia, BC blast crisis, CY cyclophosphamide, TBI
total body irradiation, MRD matched related donor, MTX
methotrexate, CR complete remission, mCR molecular
complete remission.
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